Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Multiple Sclerosis |
| Vol/bind | 17 |
| Udgave nummer | 9 |
| Sider (fra-til) | 1074-8 |
| Antal sider | 5 |
| ISSN | 1352-4585 |
| DOI | |
| Status | Udgivet - 2011 |
ID: 40194283